New drug shows promise for tough hodgkin lymphoma cases

NCT ID NCT04318080

Completed Disease control Sponsor: BeiGene Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This Phase 2 trial tested the drug tislelizumab in 46 people with classical Hodgkin lymphoma that had come back or was not responding to treatment. The main goal was to see how many participants had their tumors shrink or disappear. Participants received the drug every 3 weeks until their disease worsened or side effects became too severe.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tislelizumab (a drug that helps the immune system attack cancer cells)
What this could lead to: If successful, this could provide a new treatment option for people with Hodgkin lymphoma that has come back or not responded to other therapies.
What could go wrong: This is a small, early-phase trial (Phase 2) with only 46 participants. The drug may not work for everyone, and side effects could be severe. More research is needed before it becomes widely available.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLASSICAL HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

classic Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CLASSICAL HODGKIN LYMPHOMA

Contacts and locations

Locations

Barbara Ann Karmanos Cancer Institute

Detroit, Michigan, 48201-2013, United States
Huntsman Cancer Institute

Salt Lake City, Utah, 84112-5550, United States
Monash Health

Clayton, Victoria, VIC 3168, Australia
University of Tennessee Medical Center

Knoxville, Tennessee, 37920-1511, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.